© 2020 Marker Therapeutics, Inc.
Second Quarterly Call Earnings Call Transcript
Today TapImmune provides its business update for the second quarter 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.
TapImmune, Inc. today announced that the Company will host a conference call and live audio webcast on Thursday, August 31, 2017, at 4:30 p.m. ET, to provide a corporate and clinical update for the second quarter 2017.
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
TapImmune, Inc. today announced that, in coordination with the U.S. Food and Drug Administration (FDA), it has amended the patient inclusion criteria for its Phase 2 clinical trial of the Company’s T-cell therapeutic peptide vaccine TPIV200 to focus on women with Stage III and IV ovarian cancer who are in remission following their first round of successful platinum-based chemotherapy. TapImmune has enrolled the first women under this amended study protocol, which significantly expands the population of patients that can be addressed with TPIV 200 as a potential maintenance therapy designed to prevent disease recurrence.